NGM Biopharmaceuticals sees cash sufficient to fund operations into Q2 of 2025

NGM Biopharmaceuticals announced that, in connection with the implementation of a restructuring, the company believes that its existing cash, cash equivalents and short-term marketable securities will be sufficient to fund its operations into the second quarter of 2025. "The company has based this estimate on plans and assumptions that may prove to be insufficient or inaccurate (for example, with respect to anticipated costs, timing or success of certain activities), and the company could utilize its available financial resources sooner than it currently expects," NGM stated in a regulatory filing.